While molecularly targeted therapy has revolutionized the treatment of adenocarcinoma with genetic alterations, including the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase, treatment options for SCC are relatively limited compared to those of adenocarcinoma.3 The gene discussed is ALK; the disease is adenocarcinoma.